Urogenit Tract Infect.  2016 Dec;11(3):103-108. 10.14777/uti.2016.11.3.103.

Serum CCL11 Levels in Benign Prostatic Hyperplasia and Prostate Cancer

Affiliations
  • 1Department of Urology, Hanyang University College of Medicine, Seoul, Korea.
  • 2Department of Family Medicine, Hanyang University College of Medicine, Seoul, Korea.
  • 3Department of Environmental Biology and Medical Parasitology, Hanyang University College of Medicine, Seoul, Korea. jsryu@hanyang.ac.kr
  • 4Department of Internal Medicine, Seoul Seonam Hospital, Seoul, Korea.

Abstract

PURPOSE
CC-chemokine ligand 11 (CCL11; eotaxin-1), an eosinophil chemoattractant chemokine, has been proposed as a serum marker for prostate cancer (PCa) by two research groups. We investigated the usefulness of CCL11 in diagnosing prostatic diseases, such as benign prostatic hyperplasia (BPH) and PCa.
MATERIALS AND METHODS
CCL11 was measured in the sera of 139 men with BPH, 44 men with PCa, and 45 control men attending an outpatient health-screening clinic. A commercial enzyme-linked immunosorbent assay kit was used to measure CCL11.
RESULTS
CCL11 concentrations were significantly higher in men with BPH and PCa than in normal men (72.9±3.15 and 80.0±4.91 pg/ml vs. 57.6±8.24). In addition, a receiver operating characteristic (ROC) analysis of serum CCL11 levels showed that the areas under the ROC curves were 0.661 (p=0.001) and 0.654 (p=0.012) for BPH and PCa, respectively, compared with normal men.
CONCLUSIONS
CCL11 may be helpful in diagnosing prostatic diseases, such as BPH and PCa.

Keyword

Chemokine CCL11; Prostatic hyperplasia; Prostatic neoplasms
Full Text Links
  • UTI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr